The recent conclusion of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN) study,1 demonstrated that maximal suggested doses of both atorvastatin and rosuvastatin ameliorate atherosclerosis to a similar extent by facilitating the regression of percent atheroma volume. Both statins, however, caused renal proteinurea, albeit to different extents. The published results of the study ephemerally state that "proteinuria was commoner in the rosuvastatin group than in the atrovastatin group (3.8% versus 1.7%)". Further, the treatment group pertaining to atrorvastatin had higher number of diabetics compared to the group on rosuvastatin (16.8% versus 13.8%). Diabetes augments kidney failure,2,3 accounting for nearly 44% of new cases in the United States, therefore it is plausible the atorvastatin treatment group had more patients with renal dysfunction than the rosuvastatin treatment group whereby the actual reported percentage of patients with proteinuria on rosuvastatin might not reflect the true value.